Objective:

To outline the clinical evidence linking metabolic syndrome (MetS) to neurodegeneration, specifically peripheral neuropathy (PN) and dementia, as discussed in the review.

Approach:

• Overview of MetS and Neurodegeneration: The review discusses how MetS, which includes prediabetes, type 2 diabetes (T2D), hyperlipidemia, hypertension, and obesity, contributes to neurodegenerative processes manifesting as PN and dementia.
• Clinical Evidence Correlation: Clinical studies are reviewed to explore the correlation between PN and dementia, suggesting that PN may reflect underlying cognitive impairment.
• MetS Criteria: The review defines MetS using specific clinical criteria, emphasizing its multifactorial nature and its role as a risk factor for both PN and cognitive impairment.

Key Findings:

• Peripheral neuropathy (PN) is a common complication of diabetes, affecting up to 50% of patients with type 1 and type 2 diabetes.
• Cognitive impairment (CI) spans a spectrum from subtle dysfunction to dementia, with a significant global burden projected to rise by 2050.
• Metabolic syndrome (MetS) is linked to both PN and CI, with shared risk factors including obesity, elevated fasting glucose, dyslipidemia, and hypertension.

Interpretation:

The review suggests that the presence of PN may indicate underlying cognitive issues, highlighting the interconnectedness of metabolic dysfunction and neurodegeneration.

Limitations:

• The studies reviewed did not specifically account for dementia arising solely from diabetes.
• The review primarily focuses on correlations and does not establish direct causative pathways.

Conclusion:

The interconnection between MetS-acquired PN and dementia has implications for research, therapeutic development, and clinical care.